NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
E-Stent™ Bioelectric Stimulation Stent Technology FAQ
Designed to control regenerative protein expressions in vessel walls and surrounding tissues for a wide range of applications.
TL;DR
Leonhardt Ventures' E-Stent technology offers exclusive licensing opportunities across 29 medical applications, creating first-mover advantages in regenerative medicine markets.
The E-Stent system uses wireless wearable harnesses to deliver bioelectric signals through micro-coils embedded in stents, controlling specific protein expressions for targeted regeneration.
This wireless bioelectric stent platform could significantly improve treatment outcomes for conditions ranging from Alzheimer's to heart disease, potentially enhancing millions of lives worldwide.
Leonhardt Ventures' wireless E-Stent can stimulate proteins like klotho and sirtuins to regenerate organs from brain to pancreas using bioelectric signals.
Found this article helpful?
Share it with your network and spread the knowledge!
E-Stent™ is the first wireless, bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues, combining a next-generation implant with a wireless wearable harness.
The system uses a wireless wearable harness that delivers controlled protein expressions (bioelectric signals) to micro-coils embedded along the stent, enabling on-demand control of regenerative and healing protein expressions through wireless energy.
The technology was developed by Leonhardt Ventures LLC's R&D engineering team in Irvine, led by CTO Brian Lasater and CEO Howard Leonhardt, and was announced on Wednesday, November 19, 2025.
Stent sizes range from micro-implants smaller than a pea to 28 mm aortic stents, enabling applications across multiple organ systems including kidney regeneration, brain health, addiction treatment, memory improvement, and many other medical conditions.
According to the announcement, Leonhardt Ventures has working prototypes in testing now that are controlling regenerative and healing protein expressions on demand enabled fully by wireless energy.
Leonhardt Ventures has granted exclusive licenses to multiple entities including KidneyCell™ for kidney regeneration, CerebraCell™ for brain health and stroke recovery, AddictiStim™ for addiction treatment, MemoryStim™ for memory improvement, and BioLeonhardt™ for heart regeneration, among others.
The technology platform is licensed for applications including kidney regeneration, brain aneurysm treatment, addiction treatment, dementia and Alzheimer's treatment, severe depression, cancer treatment, hearing and vision regeneration, spinal cord injury recovery, blood pressure control, and many other conditions.
This represents a major leap forward in regenerative medical technology as it's the first wireless system that can control specific protein expressions on demand, enabling targeted regeneration and treatment across multiple organ systems through bioelectric stimulation.
Curated from Newsworthy.ai
